Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrialPhase |
gptkb:NCT04280705
|
| gptkbp:conditionStudied |
gptkb:COVID-19
|
| gptkbp:endDate |
April 2020
|
| gptkbp:fullName |
gptkb:Adaptive_COVID-19_Treatment_Trial_1
|
| https://www.w3.org/2000/01/rdf-schema#label |
ACTT-1
|
| gptkbp:location |
gptkb:Asia
gptkb:Europe gptkb:United_States |
| gptkbp:participants |
1062
|
| gptkbp:period |
Phase 3
|
| gptkbp:publishedIn |
gptkb:Beigel_JH_et_al.,_New_England_Journal_of_Medicine,_2020
|
| gptkbp:result |
time to recovery
remdesivir reduced recovery time compared to placebo |
| gptkbp:sponsor |
gptkb:National_Institute_of_Allergy_and_Infectious_Diseases
|
| gptkbp:startDate |
February 2020
|
| gptkbp:studiedDrug |
gptkb:remdesivir
placebo |
| gptkbp:bfsParent |
gptkb:remdesivir
|
| gptkbp:bfsLayer |
5
|